Page 136 - Read Online

Page 10 of 13 De Gaspari et al. Vessel Plus 2022;6:57 https://dx.doi.org/10.20517/2574-1209.2022.05

Financial support and sponsorship
MDG and CB are supported by the Registry for cardio-cerebro-vascular pathology and sudden death in the
young of the Veneto Region, Italy.

Conflicts of interest
All authors declared that there are no conflicts of interest.

Ethical approval and consent to participate
Not applicable.

Consent for publication
Not applicable.

Copyright
© The Author(s) 2022.

REFERENCES
1. Benson MD, Buxbaum JN, Eisenberg DS, et al. Amyloid nomenclature 2018: recommendations by the International Society of
Amyloidosis (ISA) nomenclature committee. Amyloid 2018;25:215-9. DOI PubMed
2. Maurer MS, Elliott P, Comenzo R, Semigran M, Rapezzi C. Addressing common questions encountered in the diagnosis and
management of cardiac amyloidosis. Circulation 2017;135:1357-77. DOI PubMed PMC
3. . Virchow, R. Über den Gang der amyloiden Degeneration. Archiv f pathol Anat 1855;8:364–8. DOI
4. Kyle RA. Amyloidosis: a convoluted story. Br J Haematol 2001;114:529-38. DOI
5. Soyka J. Über amyloide Degeneration. Prag. med. Wchnschr 165 (1876).
6. Sipe JD, Cohen AS. Review: history of the amyloid fibril. J Struct Biol 2000;130:88-98. DOI
7. Steensma DP. "Congo" red: out of Africa? Arch Pathol Lab Med 2001;125:250-2. DOI
8. Cohen AS, Calkins E. Electron microscopic observations on a fibrous component in amyloid of diverse origins. Nature
1959;183:1202-3. DOI
9. Pras M, Schubert M, Zucker-Franklin D, Rimon A, Franklin EC. The characterization of soluble amyloid prepared in water. J Clin
Invest 1968;47:924-33. DOI
10. Benson MD, Buxbaum JN, Eisenberg DS, et al. Amyloid nomenclature 2020: update and recommendations by the International
Society of Amyloidosis (ISA) nomenclature committee. Amyloid 2020;27:217-22. DOI PubMed
11. Kyle R, Linos A, Beard C, et al. Incidence and natural history of primary systemic amyloidosis in Olmsted County, Minnesota, 1950
through 1989. Blood 1992;79:1817-22. PubMed
12. Pinney JH, Smith CJ, Taube JB, et al. Systemic amyloidosis in England: an epidemiological study. Br J Haematol 2013;161:525-32.
DOI
13. Hemminki K, Li X, Försti A, Sundquist J, Sundquist K. Incidence and survival in non-hereditary amyloidosis in Sweden. BMC Public
Health 2012;12:974. DOI
14. Quock TP, Yan T, Chang E, Guthrie S, Broder MS. Epidemiology of AL amyloidosis: a real-world study using US claims data. Blood
Adv 2018;2:1046-53. DOI
15. Wechalekar AD, Gillmore JD, Hawkins PN. Systemic amyloidosis. The Lancet 2016;387:2641-54. DOI PubMed
16. Muchtar E, Dispenzieri A, Magen H, et al. Systemic amyloidosis from A (AA) to T (ATTR): a review. J Intern Med 2021;289:268-92.
DOI PubMed
17. Liao R, Jain M, Teller P, et al. Infusion of light chains from patients with cardiac amyloidosis causes diastolic dysfunction in isolated
mouse hearts. Circulation 2001;104:1594-7. DOI
18. Brenner DA, Jain M, Pimentel DR, et al. Human amyloidogenic light chains directly impair cardiomyocyte function through an
increase in cellular oxidant stress. Circ Res 2004;94:1008-10. DOI
19. Shi J, Guan J, Jiang B, et al. Amyloidogenic light chains induce cardiomyocyte contractile dysfunction and apoptosis via a non-
canonical p38alpha MAPK pathway. Proc Natl Acad Sci U S A 2010;107:4188-93. DOI
20. Bergström J, Gustavsson A, Hellman U, et al. Amyloid deposits in transthyretin-derived amyloidosis: cleaved transthyretin is
associated with distinct amyloid morphology. J Pathol 2005;206:224-32. DOI PubMed
21. Suhr OB, Lundgren E, Westermark P. One mutation, two distinct disease variants: unravelling the impact of transthyretin amyloid
fibril composition. J Intern Med 2017;281:337-47. DOI PubMed
22. Rapezzi C, Quarta CC, Obici L, et al. Disease profile and differential diagnosis of hereditary transthyretin-related amyloidosis with
exclusively cardiac phenotype: an Italian perspective. Eur Heart J 2013;34:520-8. DOI